TG Therapeutics Five Year BRIUMVI Data And What It Means For Valuation [Yahoo! Finance]
TG Therapeutics, Inc. (TGTX)
Last tg therapeutics, inc. earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.tgtherapeutics.com
Company Research
Source: Yahoo! Finance
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. TG Therapeutics published five year data from the Phase 3 ULTIMATE I & II open label extension studies of BRIUMVI in relapsing multiple sclerosis. The dataset covers thousands of patient years and reports sustained clinical efficacy, low relapse rates, and a consistent safety profile over the full period. The company positions these findings as long term clinical evidence that supports BRIUMVI's role as a core therapy option for patients with relapsing forms of MS. For investors watching TG Therapeutics, ticker NasdaqCM:TGTX, this update centers on the company's key commercial asset, BRIUMVI. The stock last closed at $30.09, with a 3 year return of 75.2%, while the 5 year return stands at a 30.5% decline, reflecting a mix of past volatility and more recent recovery. These five year data help clarify how BRIUMVI performs over time, information that physicians and payer
Show less
Read more
Impact Snapshot
Event Time:
TGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025 [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics Inc (TGTX) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics (TGTX) Q4 2025 Earnings Transcript [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics outlines $825M–$850M BRIUMVI 2026 guidance while accelerating subcutaneous program [Seeking Alpha]Seeking Alpha
TGTX
Earnings
- 2/26/26 - Miss
TGTX
Sec Filings
- 2/27/26 - Form 10-K
- 2/26/26 - Form 8-K
- 1/29/26 - Form 4
- TGTX's page on the SEC website